Elevation of the tumor marker CA19‐9 in a pancreatic cancer survivor with benign prostatic hyperplasia: A clinical case report
Key Clinical Message Serum carbohydrate antigen 19‐9 (CA19‐9) is used for recurrence surveillance in patients with resected pancreatic ductal adenocarcinoma (PDAC). This report describes the association of increasing CA19‐9 in a male PDAC survivor with presence of prostatic hyperplasia. Unexplained...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-06-01
|
| Series: | Clinical Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ccr3.8929 |